GeoVax Labs Inc. (NASDAQ:GOVX) Sees Large Increase in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 367,575 shares, a growth of 101.6% from the August 15th total of 182,364 shares. Currently, 5.0% of the shares of the company are short sold. Based on an average trading volume of 2,024,690 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Several brokerages have issued reports on GOVX. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. Finally, Noble Financial restated an “outperform” rating on shares of GeoVax Labs in a research report on Tuesday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, GeoVax Labs currently has an average rating of “Hold” and a consensus target price of $150.00.

GeoVax Labs Trading Down 1.6%

Shares of NASDAQ:GOVX traded down $0.01 during midday trading on Wednesday, hitting $0.41. The stock had a trading volume of 119,617 shares, compared to its average volume of 2,032,415. GeoVax Labs has a 1 year low of $0.41 and a 1 year high of $17.74. The stock has a 50 day moving average price of $0.73 and a two-hundred day moving average price of $1.26. The company has a market capitalization of $3.04 million, a PE ratio of -0.04 and a beta of 3.66.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Monday, July 27th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. As a group, equities analysts expect that GeoVax Labs will post -4.94 EPS for the current year.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.